Literature DB >> 51344

Shedding of infectious virus/antibody complexes from vesicular lesions of patients with recurrent herpes labialis.

C A Daniels, S G LeGoff.   

Abstract

The concentration of herpes-simplex virus (H.S.V.) in the lesions of adults with recurrent herpes labialis was determined. On the 1st day the vesicle appeared, the fluid within the lesion contained 10(5-3) plaque-forming units (P.F.U.) of H.S.V./mul. By swabbing the surface of the lesions with a sterile pledget, 10(6-2) P.F.U. of virus was isolated from the inflamed labial mucosa. The amount of virus obtained from the labial surface decreased on the 2nd and 3rd day to 10(5-0) and 10(3-0) P.F.U., respectively. In two patients on immunosuppressive drugs, high concentrations of virus (greater than 10(4-0) P.F.U.) were obtained per swab for more than 3 weeks. The presence of infectious virus-antibody (V.A.) complexes in herpetic lesions was demonstrated by examining fifty-two isolates from twenty-eight patients at various times during the course of their disease. 71% of the patients had V.A. complexes in their lesions on the 1st day of the vesicular eruption, and by the 3rd day all of the lesions examined contained complexes. It is concluded that patients with active lesions shed high concentrations of virus and that natural infection may be transmitted by an infectious V.A. complex.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51344     DOI: 10.1016/s0140-6736(75)90896-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Immune interferon production by lymphoid cells: role in the inhibition of herpesviruses.

Authors:  L A Babiuk; B T Rouse
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

Review 2.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

3.  Enhanced antiglobulin-mediated neutralization of herpes simplex virus-IgG complexes by complement and heterologous anti-immunoglobulin.

Authors:  J C Shivers; C A Daniels
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

4.  Neutralising antibody in mice with primary and recurrent herpes simplex virus infection.

Authors:  J M Darville; W A Blyth
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Comparison of fluorescent-antibody, neutralizing-antibody, and complement-enhanced neutralizing-antibody assays for detection of serum antibody to respiratory syncytial virus.

Authors:  T N Kaul; R C Welliver; P L Ogra
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

6.  Scanning and transmission electron microscopic studies of complement-mediated lysis and antibody-dependent cell-mediated cytolysis of herpes simplex virus-infected human fibroblasts.

Authors:  C A Daniels; S Bodner; K F Trofatter
Journal:  Am J Pathol       Date:  1980-09       Impact factor: 4.307

7.  Application and tolerability of Herpotherm(®) in the treatment of genital herpes.

Authors:  Gerrit Schlippe; Werner Voss; Lars Christian Brenn
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-06-05

8.  Persistent viral infections as models for research in virus chemotherapy.

Authors:  G Streissle
Journal:  Adv Virus Res       Date:  1981       Impact factor: 9.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.